D02.3

Clinical Causes: Chronic exposure to airborne irritants like tobacco smoke or industrial pollutants Long-term viral infections, such as human papillomavirus (HPV) or Epstein-Barr virus (EBV), which are linked to cellular mutations Genetic predispositions influencing cell growth regulation Environmental factors including exposure to certain chemicals, dust, or toxins History of previous respiratory tract cancers or precancerous lesions

Key Symptoms: Persistent nasal congestion or obstruction Unexplained nasal bleeding Mucosal ulcers or sores that do not heal Facial pain or swelling in the affected area Reduced or loss of sense of smell or taste Ear fullness or hearing difficulties if involving the middle ear Discharge from the nose or ear that may be bloody or overgrown

Diagnosis Path: Diagnosis of carcinoma in situ in these regions involves several steps: - Endoscopic examination of the nasal cavities, accessory sinuses, and middle ear to visually identify abnormal tissue. - Biopsy of suspicious areas to examine cellular characteristics under a microscope. - Imaging studies such as CT scans or MRIs to assess the extent of localized lesions and involvement of adjacent structures. - Possible use of specialized techniques like brush cytology or narrow-band imaging for enhanced visualization. Since CIS is confined to the epithelial layer, early detection through biopsy and imaging is critical for appropriate management.

Treatment Protocols: The primary goal of treating carcinoma in situ of the respiratory system is to eliminate the abnormal cells before they invade deeper tissues. - Surgical removal of the lesion using minimally invasive techniques, such as endoscopic sinus surgery. - Laser ablation or cauterization for localized CIS lesions. - Topical therapies, including immunotherapy or chemopreventive agents, might be considered in certain cases. - Regular follow-up with endoscopic examinations and biopsies to monitor for recurrence. - In some cases, radiation therapy may be employed if surgical options are limited. Early intervention is essential to prevent progression to invasive carcinoma, which might involve more extensive treatments and carry a higher risk of complications.